Nanobiotix gets green light for liver cancer trial

Nanobiotix, the developer of nano-medical technology, has been given clearance to start a new clinical trial for its lead NanoXray product, NBTXR3. The test will evaluate the use of NBTXR3 in conjunction with high precision radiation therapy, delivered as high dose fractions, known as Stereotatic Body Radiotherapy.

Proactive Investors